CX3 CR1 delineates temporally and functionally distinct subsets of myeloid-derived suppressor cells in a mouse model of ovarian cancer

Immunology and Cell Biology

Volumn 92, Issue 6, 2014, Pages 499-508

  Hart, Kevin M ^a   Usherwood, Edward J ^a   Berwin, Brent L ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 10; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, MOUSE; IL10 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BONE MARROW CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; INTRACELLULAR SPACE; MACROPHAGE; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; OVARY TUMOR; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; FEMALE; INTERLEUKIN-10; MICE; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RECEPTORS, CHEMOKINE; TUMOR MICROENVIRONMENT;

EID: 84904036449     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.13     Document Type: Article

References (31)

1. Geissmann F, Auffray C, Palframan R, Wirrig C, Ciocca A, Campisi L et al. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol 2008; 86: 398-408. (Pubitemid 351948210)
2. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82. (Pubitemid 36859902)
3. Kayama H, Ueda Y, Sawa Y, Jeon SG, Ma JS, Okumura R et al. Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis. Proc Natl Acad Sci USA 2012; 109: 5010-5015.
4. Rivollier A, He J, Kole A, Valatas V, Kelsall BL. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med 2012; 209: 139-155.
5. Clover AJ, Kumar AH, Caplice NM. Deficiency of CX3CR1 delays burn wound healing and is associated with reduced myeloid cell recruitment and decreased sub-dermal angiogenesis. Burns 2011; 37: 1386-1393.
6. Bonduelle O, Duffy D, Verrier B, Combadiere C, Combadiere B. Cutting edge: Protective effect of CX3CR1+ dendritic cells in a vaccinia virus pulmonary infection model. J Immunol 2012; 188: 952-956.
7. Donnelly DJ, Longbrake EE, Shawler TM, Kigerl KA, Lai W, Tovar CA et al. Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci 2011; 31: 9910-9922.
8. Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T et al. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010; 52: 1769-1782.
9. Hart KM, Bak SP, Alonso A, Berwin B. Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer. Neoplasia 2009; 11: 564-573.
10. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011; 60: 1512-1518.
11. Zeyda M, Gollinger K, Kriehuber E, Kiefer FW, Neuhofer A, Stulnig TM. Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int J Obes (Lond) 2010; 34: 1684-1694.
12. Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol 2008; 181: 4208-4218.
13. Ishida Y, Gao JL, Murphy PM. Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol 2008; 180: 569-579.
14. Tighe RM, Li Z, Potts EN, Frush S, Liu N, Gunn MD et al. Ozone inhalation promotes CX3CR1-dependent maturation of resident lung macrophages that limit oxidative stress and inflammation. J Immunol 2011; 187: 4800-4808.
15. Bak SP, Alonso A, Turk MJ, Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol 2008; 46: 258-268.
16. Bak SP, Walters JJ, Takeya M, Conejo-Garcia JR, Berwin BL. Scavenger receptor-Atargeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 2007; 67: 4783-4789. (Pubitemid 46910186)
17. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008; 68: 7684-7691.
18. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009; 69: 7329-7337.
19. Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2011; 2: 29.
20. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176: 5023-5032.
21. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG et al. 'Reeducating' tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205: 1261-1268. (Pubitemid 351831483)
22. Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 2006; 26: 1715-1718.
23. Mustea A, Braicu EI, Koensgen D, Yuan S, Sun PM, Stamatian F et al. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine 2009; 45: 8-11.
24. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010; 31: 375-383.
25. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-4114. (Pubitemid 30314508)
26. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol 2007; 8: 931-941. (Pubitemid 47300007)
27. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-983.
28. Fogg DK, Sibon C, Miled C, Jung S, Aucouturier P, Littman DR et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 2006; 311: 83-87. (Pubitemid 43063063)
29. Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N et al. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J Exp Med 2009; 206: 595-606.
30. Murch AR, Grounds MD, Papadimitriou JM. Improved chimaeric mouse model confirms that resident peritoneal macrophages are derived solely from bone marrow precursors. J Pathol 1984; 144: 81-87. (Pubitemid 15202420)
31. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ et al. Tumor-infiltrating dendritic cell precursors recruited by a betadefensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10: 950-958. (Pubitemid 39273736)